Golden
Perception Therapeutics

Perception Therapeutics

Gene therapy company for inherited retinal diseases.

All edits

Edits on 12 May 2019
Harris Landon
Harris Landon approved a suggestion from Golden's AI on 12 May 2019 9:32 am
Edits made to:
Article (+13/-13 characters)

Article

Dr. Petersen-Jones has worked as head of the OphthalmologyOphthalmology Service at University of Edinburgh, and was later a Wellcome Trust Veterinary Research Career Development Fellow at the University of Cambridge, UK where he was awarded a PhD for his research into hereditary retinal diseases in dogs. He has been on the faculty at Michigan State University since 1998.

Edits on 7 May 2019
Miguel Almonte
Miguel Almonte approved a suggestion from Golden's AI on 7 May 2019 11:27 pm
Edits made to:
Article (+20/-20 characters)

Article

Dr. Trevor McGill received his Ph.D. from the University of Lethbridge in 2008 and subsequently joined the Casey Eye Institute at OHSU as a post doctoral fellow. In 2011, Dr. McGill joined the faculty at the Casey Eye Institute as Research Assistant Professor. Dr. McGill's lab uses both rodent and nonhuman primate models of Retinitis PigmentosaRetinitis Pigmentosa and Age-related Macular Degeneration to aid in the translation of cell-based and gene therapies for retinal degenerative disease into clinical trials.

Jude Gomila
Jude Gomila edited on 7 May 2019 8:19 pm
Edits made to:
Infobox (+1 properties)
Description (+52 characters)
Article (+2159 characters)
People (+1 rows) (+2 cells) (+28 characters)
Topic thumbnail

Perception Therapeutics

Gene therapy company for inherited retinal diseases.

Article

Team

Dr. Petersen-Jones has worked as head of the Ophthalmology Service at University of Edinburgh, and was later a Wellcome Trust Veterinary Research Career Development Fellow at the University of Cambridge, UK where he was awarded a PhD for his research into hereditary retinal diseases in dogs. He has been on the faculty at Michigan State University since 1998.



Dr. William Hauswirth received his B.S. in Chemistry from Stanford University and his Ph.D in Physical Chemistry from Oregon State University. After an NIH Fellowship in the Biochemistry Department at Johns Hopkins University, he joined that department as an Assistant Professor. In 1976, he joined the faculty of Molecular Genetics and in 1985 the Ophthalmology faculty at the University of Florida College of Medicine.



Dr. Trevor McGill received his Ph.D. from the University of Lethbridge in 2008 and subsequently joined the Casey Eye Institute at OHSU as a post doctoral fellow. In 2011, Dr. McGill joined the faculty at the Casey Eye Institute as Research Assistant Professor. Dr. McGill's lab uses both rodent and nonhuman primate models of Retinitis Pigmentosa and Age-related Macular Degeneration to aid in the translation of cell-based and gene therapies for retinal degenerative disease into clinical trials.



Dr. Brian Mansfield received an honors degree in physical chemistry from Canterbury University, a Ph.D. in biochemistry from the University of Otago, New Zealand, and did post-doctoral training in molecular genetics at the Johns Hopkins University School of Medicine with Nobel Laureate Professor Dr. Daniel Nathans.

...

Prior to joining the Foundation, Dr. Mansfield was the vice president for research and development for Correlogic Systems, Inc., a biotechnology company developing technology for the early detection and diagnosis of cancer. Prior to that role, Dr. Mansfield spent five years as a senior scientist in protein development at Human Genome Sciences, Inc. Before joining HGSI, Dr. Mansfield spent 12 years as a tenured professor of eukaryotic genetics at Massey University, New Zealand and three years as a visiting professor at Georgetown University, Washington D.C.

People

Name
Role
Related Golden topics

Omid Karkouti

Founder and CEO



Infobox

Jude Gomila"Initial topic creation"
Jude Gomila created this topic on 7 May 2019 8:16 pm
Edits made to:
Topic thumbnail

 Perception Therapeutics

Gene therapy company for inherited retinal diseases.

No more activity to show.